– USA, MA – Atea Pharmaceuticals, Inc. (Nasdaq: AVIR), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, announced the appointment of Arthur Kirsch to its Board of Directors, effective immediately, bringing decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries.
About Arthur S. Kirsch
Arthur Kirsch is a Senior Advisor with Alvarez & Marsal’s Life Sciences Industry Group, and throughout his 30-year career has held numerous roles in mergers and acquisitions and equity capital markets at global investment banks. Over that time, he executed a wide range of strategic advisory assignments for clients in the healthcare and life sciences industries as well as numerous public and private financings.
Since July 2019, Arthur has served as a Senior Advisor with Alvarez & Marsal’s Life Sciences Industry Group. From June 2005 until June 2019, he served as a Managing Director and Senior Advisor for GCA Global, LLC, a global investment banking firm. From May 1994 to May 2004, he served as Head of Research at Vector Securities, LLC, a brokerage firm. Before that, Arthur served as CEO of NatWest Securities Limited, where he was responsible for managing the global securities business. Mr. Kirsch began his career at Drexel Burnham Lambert, Inc., an investment banking firm.
Arthur serves on the Board of Directors of Liquidia Technologies, Inc. (Nasdaq: LQDA). He previously served on the Board of Kadmon Holdings, Inc. (NYSE: KDMN), where he was a member of the Transaction Committee involved in overseeing its sale to Sanofi, as well as Immunomedics, POZEN Inc. and Aralez, Inc.
Arthur received his B.A. in Finance from the University of Rhode Island and earned his MBA in Finance from Bernard M. Baruch College.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry, and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single-stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleus (t)ide platform with other classes of antivirals that may be used in combination with its nucleus s(t)ide product candidates. Our lead program and current focus are on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat the hepatitis C virus.
For more information: https://ateapharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.